Company Description
NAYA Biosciences, Inc., a life science portfolio company, develops clinical stage assets to treat patients with fertility, oncology, and autoimmune diseases.
The company operates in two divisions, NAYA Women’s Health and NAYA Therapeutics. Its lead product includes NY-303, a GPC3-targeted FLEX-NK bispecific antibody that is in Phase I/II clinical trials for hepatocellular carcinoma, as well as solid and pediatric tumors; and NY-338, a CD38-targeted FLEX-NK bispecific antibody for multiple myeloma and autoimmune diseases.
The company also offers INVOcell, a a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body.
The company was formerly known as INVO Bioscience, Inc. and changed its name to NAYA Biosciences, Inc. NAYA Biosciences, Inc. was founded in 2007 and is based in Sarasota, Florida.
| Country | United States |
| Founded | 2007 |
| Industry | Medical Devices |
| Sector | Healthcare |
| CEO | Steven Shum |
Contact Details
Address: 5582 Broadcast Court Sarasota, Florida 34240 United States | |
| Phone | 978-878-9505 |
| Website | nayabiosciences.com |
Stock Details
| Ticker Symbol | NAYA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001417926 |
| ISIN Number | US44984F4019 |
| Employer ID | 20-4036208 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Steven M. Shum | Chief Executive Officer and Director |
| Dr. Daniel Gedeon Teper MBA, PharmD | President and Director |
| Andrea Goren | Chief Financial Officer |
| Anna Baran-Djokovic J.D. | Senior Vice President of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 24, 2025 | 8-K | Current Report |
| Mar 12, 2025 | DEFR14A | Filing |
| Mar 7, 2025 | 8-K | Current Report |
| Feb 25, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 13, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Feb 11, 2025 | DEF 14A | Other definitive proxy statements |
| Jan 31, 2025 | PRE 14A | Other preliminary proxy statements |
| Jan 16, 2025 | SCHEDULE 13G | Filing |
| Jan 16, 2025 | 8-K | Current Report |
| Jan 15, 2025 | SCHEDULE 13G | Filing |